Physician
Pediatric Hematology & Oncology
Dr. Luis A. Clavell, MD
|
|
Give Review
Dr. Luis A. Clavell is an expert in the field of Pediatric Hematology & Oncology. He researched medicine at University of Puerto Rico School of Medicine. Dr. Luis A. Clavell is a published doctor. He has 41 publications published. The most current publication "Giant platelets with abnormal surface glycoproteins: a new familial disorder associated with mitral valve insufficiency."
Publications
- Intravenous pegylated asparaginase versus intramuscular native Escherichia colil-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001):...
- Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
- Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
- Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
- Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
- The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
- Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment.
- Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
- Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.
- Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).
- Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
- Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
- The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Da...
- Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
- Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995).
- Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia.
- Giant platelets with abnormal surface glycoproteins: a new familial disorder associated with mitral valve insufficiency.
- Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985.
- Use of monoclonal antibodies as diagnostic and therapeutic reagents in acute lymphoblastic leukemia.
- Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors.
- Serotherapy of acute lymphoblastic leukemia with monoclonal antibody.
- Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience.
- Acute lymphoblastic leukemia in Puerto Rican children. 73 consecutive cases.
- Efficacy and morbidity of central nervous system "prophylaxis" in childhood acute lymphoblastic leukemia: eight years' experience with cranial irradiation and intrathe...
- Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement.
- Hemolytic interaction of Newcastle disease virus and chicken erythrocytes. 3. Cessation of the reaction as a result of inactivation of hemolytic activity by erythrocytes.
- Hemolytic interaction of Newcastle disease virus and chicken erythrocytes. II. Determining factors.
- Hemolytic interaction of Newcastle disease virus and chicken erythrocytes. I. Quantitative comparison procedure.
- Relationship between the ribonucleic acid synthesizing capacity of ultraviolet-irradiated Newcastle disease virus and its ability to induce interferon.
- Piperacillin and gentamicin as non toxic empirical therapy in pediatric patients with fever and neutropenia.
- Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.
- Therapy for pediatric aplastic anemia; 7 years experience at the Puerto Rico Pediatric Oncology Program.
- Treatment outcome in children with malignancies associated with human immunodeficiency virus infection.
- Intensive sequential chemotherapy for children with acute myelogenous leukemia.
- Surgery only for the treatment of patients with stage I (Cassady) Wilms' tumor.
- Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update).
- Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia.
- Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze.
- Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, ran...
Schools
New York University
University of Puerto Rico Medical Sciences Campus
University Calif Davis
Chldns Hospital
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Education
-
Boston Children's Hospital -
University of California Davis -
University of Puerto Rico School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Maribel C. Garcia, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Myrna S. Figueroa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gloria G. Colon, MD
This Doctor is OpenDoctor Recommended.
|